Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Net Income (2019 - 2025)

Allogene Therapeutics' Net Income history spans 7 years, with the latest figure at -$41.3 million for Q3 2025.

  • For Q3 2025, Net Income rose 36.6% year-over-year to -$41.3 million; the TTM value through Sep 2025 reached -$209.6 million, up 23.65%, while the annual FY2024 figure was -$257.6 million, 21.29% up from the prior year.
  • Net Income for Q3 2025 was -$41.3 million at Allogene Therapeutics, up from -$50.9 million in the prior quarter.
  • Across five years, Net Income topped out at $1.9 million in Q4 2021 and bottomed at -$99.1 million in Q1 2023.
  • The 5-year median for Net Income is -$66.4 million (2024), against an average of -$65.0 million.
  • The largest annual shift saw Net Income soared 102.76% in 2021 before it crashed 5195.67% in 2022.
  • A 5-year view of Net Income shows it stood at $1.9 million in 2021, then plummeted by 5195.67% to -$96.5 million in 2022, then grew by 18.26% to -$78.8 million in 2023, then grew by 27.02% to -$57.5 million in 2024, then rose by 28.2% to -$41.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Net Income are -$41.3 million (Q3 2025), -$50.9 million (Q2 2025), and -$59.8 million (Q1 2025).